210 IPOs and Counting: The 2026 Issuance Machine Keeps Running

The 2026 IPO market is not booming. It is functioning — and that distinction matters more than the headline number.

Through July 29, 210 companies have gone public on US exchanges, a 7.14% increase over the 196 IPOs recorded by the same date in 2025^[1]. That is a healthy pace, but it is not a frenzy. What it signals is that the new-issues pipeline has unblocked: underwriters are pricing deals, institutional accounts are absorbing them, and the market is clearing supply without the pent-up pressure that builds when the window slams shut. The more telling question is what happens after the first print — and there, the dispersion is extreme.

The Week Ahead: Three Deals That Tell Different Stories

The final trading days of July carry a cluster of IPOs that span restaurant franchising, sustainable fashion, and late-stage biotech — a useful cross-section of what the 2026 market will and will not fund.

Jersey Mike’s Subs (JMKE) is scheduled to price July 30 on the NYSE at $21–$25 per share, offering 43.5 million shares for a potential raise near $1 billion^[2]. Backed by Blackstone, the sandwich franchise represents the private-equity-exit cohort that 2026’s open window was supposed to unlock. A deal of this size — roughly $1 billion in gross proceeds — tests whether institutional demand extends beyond AI and biotech into consumer-franchise equity.

Reformation (REF) prices the same day on the NYSE at $15–$17, with 14.1 million shares targeting approximately $225 million^[2]. The sustainable women’s apparel brand occupies a category — direct-to-consumer fashion — that has produced more IPO cautionary tales than success stories over the past decade. Its reception will be a read on whether the market rewards growth-stage consumer brands or demands profitability proof first.

Apnimed (APMD) prices July 31 on Nasdaq at $14–$16, with 10 million shares for a maximum raise of $160 million^[3]. The Massachusetts biotech’s lead candidate, Oxnimbi (AD109), is an oral pill for obstructive sleep apnea awaiting an FDA decision expected by February^[3]. The drug has cleared two Phase 3 trials, most recently reducing nightly apnea events by 46.8% in a 660-patient study^[4]. If approved, it would become the first prescription drug designed specifically for sleep apnea — Eli Lilly’s Zepbound was approved for the condition in December 2024 but only for patients who also have obesity^[3]. Apnimed is raising capital to fund a commercial launch before that approval arrives, which is the classic late-stage biotech IPO wager: pay now for infrastructure, collect later if the regulator agrees.

What the Recent Class Shows: Brutal Dispersion

The 2026 IPO cohort is not a monolith. It is a barbell — and the distance between the two ends is widening.

Consider the standout performers. Hemab Therapeutics (COAG), which went public May 1 at $18, has returned roughly 153% to trade near $44.75^[1]. Parabilis Medicines (PBLS), IPO’d June 10 at $20, sits at $31.78 — up about 59%^[1]. Swarmer (SWMR), a March 17 debut at $5, has delivered a staggering 637% return to trade near $36.84^[1]. Scribe Therapeutics (SCTX), which priced July 24 at $15, is already at $18.36 in early trading — a 22% gain^[5]. These are biotech and small-cap technology names where the market is clearly willing to pay for clinical or technological optionality.

Now look at the wreckage. Standard Nuclear (STDN), which IPO’d July 16 at $15, has collapsed to $7.33 — a 51.9% loss^[1]. ERock (EROC), a June 10 debut at $21.50, is at $8.99, down 57.3%^[1]. DSC Holdings (DSC), priced June 25 at $17, trades at $5.41 — a 69.2% decline^[1]. Exyn Technologies (EXYN), a May 15 listing at $7.75, has fallen to $2.32, losing 67.7%^[1]. These are not isolated misses; they represent a consistent pattern where speculative or pre-revenue debuts are being punished swiftly and severely.

The marquee names from earlier in the year tell a more ambiguous story. Cerebras Systems (CBRS), the AI chip company that was 2026’s largest IPO at $185 per share on May 14, surged to an intraday high of $385 on its first day before closing at $311^[6]. It has since given back those gains to trade near $169.39 — down roughly 8.4% from its IPO price and well off its first-day peak^[1]. SpaceX (SPCX), which went public June 11 at $135, currently trades at $112.55 as of the July 29 close, down about 16.6% from its offering price^[5]. SK hynix (SKHY), the Korean memory-chip giant that listed its ADRs July 9 at $149, sits at $126.79 — off 14.9%^[5]. Bending Spoons (BSP), the Italian app maker that debuted July 1 at $29, is a rare bright spot at $32.70, up roughly 14%^[1].

The pattern: the market is funding innovation and optionality but marking down anything that smells like hype without near-term proof. The first-day pop is no longer a reliable signal of sustained demand.

The Pipeline Behind the Pipeline

GrubMarket, a food-tech and supply-chain company, confidentially filed for a US IPO on July 28, targeting a valuation near $4.5 billion^[7]. The company reportedly generated $550 million in revenue, though its S-1 will carry a mandatory disclosure related to a revenue overstatement settlement — the kind of baggage that tests whether the open window tolerates imperfect histories or only clean ones^[7].

That filing matters because it extends the pipeline beyond this week’s cluster. Confidential submissions — the mechanism that lets companies draft their S-1 with the SEC before public disclosure — are the leading indicator of supply six to twelve months out. GrubMarket’s entry, alongside the steady drip of SPACs and small-cap listings visible in the Stock Analysis data^[1], suggests the issuance cadence is structural rather than event-driven.

Market Structure: The Plumbing Has Changed

Citadel Securities’ 1H 2026 Market Structure & Flows review, published June 30, lays out a market that bears little resemblance to the one most investors learned to navigate over the past two decades^[8]. Five structural forces are worth tracking because they shape how new issues are received:

Concentration. The ten largest companies now account for nearly 40% of the S&P 500, near record levels^[8]. Semiconductors alone represent nearly one-fifth of the index — the highest share on record, having quadrupled since June 2020^[8]. When the top of the market is this heavy, new IPOs compete for attention and capital against a narrow group of mega-caps that absorb passive flows by construction.

Passive dominance. ETFs have attracted $1.2 trillion in net inflows year-to-date through June, running 45% ahead of last year’s record pace^[8]. Passive vehicles do not buy IPOs at the offering; they buy them when they enter indices. The lag between listing and index inclusion is a structural feature of the modern market that dampens early-day demand from the largest pool of incremental capital.

Retail as structural bid. Average daily retail equity volumes in May and June were running 65% above 2025 levels and more than double the 2024 average^[8]. June 12 marked the largest single day of retail net buying ever observed on Citadel’s platform, surpassing the previous record by 50%^[8]. Retail investors are concentrated in the same sectors driving benchmarks — semiconductors and broad ETFs — rather than diversifying into new issues^[8]. This means the retail bid that supports the market overall does not automatically translate into IPO demand unless the debut is in a sector retail already favors.

Leverage and 0DTE. One in three listed options now expires the same day, and nearly half of retail options volume trades in zero-days-to-expiration contracts^[8]. Leveraged ETF assets reached a record $218 billion, up 60% since March alone, led by technology (+136%) and semiconductor (+175%) exposures^[8]. This leverage is concentrated in leadership sectors, not spread across the IPO universe — which means amplified price discovery for the top names and thinner sponsorship for everything else.

Volatility regime. Three-month implied correlations fell to their lowest level in more than 15 years, reflecting one of the strongest stock-picker’s markets in history^[8]. Semiconductor implied volatility has more than doubled over the past decade, from 32% in 2016 to nearly 72%^[8]. Nearly 70% of Nasdaq rallies in May were accompanied by higher implied volatility — the “spot-up/vol-up” pattern that is more than 3x the long-run average^[8]. For IPOs, low correlation means each deal is judged on its own merits rather than carried by a sector wave — which is precisely why the dispersion between winners and losers is so extreme.

Checklist: What Separates the 2026 IPO Winners From the Wreckage

This is not a sector screen so much as a proof screen. The 2026 market funds optionality when the optionality is backed by data — clinical endpoints, shipping product, demonstrated revenue. It punishes narrative.

What to Watch Next

1. Jersey Mike’s pricing and first-day action (July 30). A $1 billion consumer-franchise IPO is a different animal than a $160 million biotech deal. If JMKE prices within range and holds, it signals the window has broadened beyond healthcare and tech. If it cuts price or breaks issue, the window may be narrower than the headline count suggests.

2. Apnimed’s FDA timeline. The PDUFA date expected by February 2026 is the binary event that determines whether the IPO raise was well-timed or premature. Between now and then, the stock’s trading pattern will reflect optionality pricing — a profile that historically produces high volatility and sharp repricing on any regulatory news.

3. GrubMarket’s S-1 public filing. The confidential submission becomes a public document when the company is ready to launch its roadshow. The revenue-overstatement disclosure will test whether the market tolerates imperfect histories in a window that is open but selective.

4. Post-lockup selling pressure. The first lockup expirations for the spring 2026 IPO class — including Cerebras, SpaceX, and Parabilis — will arrive in the August–October window. How those newly freed insider shares are absorbed is a structural test of secondary-market depth.

5. Semiconductor volatility and its spillover. With semiconductor implied volatility near 72% and leveraged ETF assets concentrated in the sector, any sharp move in the chip complex could ripple through the risk appetite that supports new-issue pricing. The “spot-up/vol-up” regime cuts both ways: when it reverses, the unwind can be swift.

The 2026 IPO market is doing what a healthy new-issues market should do: clearing supply, rewarding proof, and punishing speculation. The 7% volume increase over last year is real but unspectacular. What matters more is the dispersion — the gap between triple-digit biotech winners and 50%-plus debuts that collapse within weeks. In a market where implied correlations are at 15-year lows and passive flows go to whatever is already in the index, each IPO stands or falls on its own merits. That is not a broken market. It is a market that has learned to discriminate.

FN2 Research provides market commentary and education, not personalized investment advice. IPO investing carries significant risk, including the potential loss of principal. Past performance does not guarantee future results.